These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 18465473)
1. Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives. El-Ibiary SY; Cocohoba JM Eur J Contracept Reprod Health Care; 2008 Jun; 13(2):123-32. PubMed ID: 18465473 [TBL] [Abstract][Full Text] [Related]
2. Drug interactions between antiretrovirals and hormonal contraceptives. Tseng A; Hills-Nieminen C Expert Opin Drug Metab Toxicol; 2013 May; 9(5):559-72. PubMed ID: 23425052 [TBL] [Abstract][Full Text] [Related]
10. Contraception in women with epilepsy: pharmacokinetic interactions, contraceptive options, and management. Dutton C; Foldvary-Schaefer N Int Rev Neurobiol; 2008; 83():113-34. PubMed ID: 18929078 [TBL] [Abstract][Full Text] [Related]
11. [Effect of hormonal contraception on bone mineral density]. Trémollières F Gynecol Obstet Fertil; 2005; 33(7-8):520-5. PubMed ID: 16005661 [TBL] [Abstract][Full Text] [Related]
12. Contraception in the context of HIV/AIDS: a review. Agboghoroma CO Afr J Reprod Health; 2011 Sep; 15(3):15-23. PubMed ID: 22574489 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic drug interactions between antiretrovirals and oral contraceptives. Tittle V; Bull L; Boffito M; Nwokolo N Clin Pharmacokinet; 2015 Jan; 54(1):23-34. PubMed ID: 25331712 [TBL] [Abstract][Full Text] [Related]
14. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives. Kearney BP; Mathias A Pharmacotherapy; 2009 Aug; 29(8):924-9. PubMed ID: 19637945 [TBL] [Abstract][Full Text] [Related]
15. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients? Cuzin L; Allavena C; Morlat P; Dellamonica P AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976 [TBL] [Abstract][Full Text] [Related]
16. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program. Jaspan HB; Berrisford AE; Boulle AM Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556 [TBL] [Abstract][Full Text] [Related]
17. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations. Pinheiro Edos S; Antunes OA; Fortunak JM Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246 [TBL] [Abstract][Full Text] [Related]
18. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières. Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy. Nanda K; Amaral E; Hays M; Viscola MA; Mehta N; Bahamondes L Fertil Steril; 2008 Oct; 90(4):965-71. PubMed ID: 17880953 [TBL] [Abstract][Full Text] [Related]